+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lipodystrophy Syndrome (LS)- Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4702065
  • Drug Pipelines
  • December 2018
  • Region: Global, Global
  • 100 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Ionis Pharmaceuticals
  • Zydus Cadila
  • MORE
Lipodystrophy Syndrome (LS)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lipodystrophy Syndrome (LS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lipodystrophy Syndrome (LS) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Lipodystrophy Syndrome (LS) - Disease Understanding and Treatment Algorithm

Lipodystrophies are a group of rare disorders of diverse etiology which are characterized by variable loss of body fat. The loss of body fat may affect nearly the entire body (generalized), only certain body regions (partial) or small areas under the skin (localized). Depending upon the severity and extent of body fat loss, patients may be predisposed to metabolic complications associated with insulin resistance. These metabolic complications include early onset of diabetes mellitus, hypertriglyceridemia and hepatic steatosis.

There are many different types of lipodystrophy. It can be acquired, or genetic (inherited). The inherited form may be present at birth or develop during childhood (congenital). It may result in fat loss in only one area of the body or throughout the body (generalized).

Generalized lipodystrophy refers to the situation in which the fat tissue throughout the body is affected (sometimes mistaken for weight or fat gain).

Partial, or localized, lipodystrophy affects only one area of the body and is not associated with abnormal health generally.

The Lipodystrophy Syndrome (LS) market report gives the thorough understanding of the Lipodystrophy Syndrome (LS) by including details such as disease definition, type, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Lipodystrophy Syndrome (LS) in the US, Europe, and Japan.

Lipodystrophy Syndrome (LS) Epidemiology

The Lipodystrophy Syndrome (LS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalent Population of Lipodystrophy Syndrome (LS), Type Specific Prevalent of Lipodystrophy Syndrome (LS), Diagnosed and Treatable Cases of Lipodystrophy Syndrome (LS)] scenario of Lipodystrophy Syndrome (LS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

As per Elaine Chiquette et. Al., the estimated prevalence of diagnosed Lipodystrophy Syndrome (LS) was 3.07 cases/million (95% confidence interval [CI], 2.30-4.02), 0.23 cases/million (95% CI, 0.06-0.59) and 2.84 cases/million (95% CI, 2.10-3.75) for generalized lipodystrophy (GL) and partial lipodystrophy (PL), respectively.

According to Orphanet registry, Primary lipodystrophies prevalence has been estimated at less than 1 case in 100 000.

This research estimates that the prevalent population of Lipodystrophy Syndrome (LS) will significantly change during the study period [2016-2027].

Lipodystrophy Syndrome (LS) Drug Chapters

This segment of the Lipodystrophy Syndrome (LS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current therapies prevent or ameliorate the comorbidities of Lipodystrophy Syndrome (LS). At present, Myalept (Bristol-Myers Squibb) (recombinant human methionyl leptin) is the only drug approved specifically for lipodystrophy. It is approved in the United States as an adjunct to diet for treatment of metabolic complications in patients with generalized lipodystrophy.

Key players such as Ionis Pharmaceuticals, Zydus Cadila and many others are involved in developing therapies for Lipodystrophy Syndrome (LS). Expected launch of emerging therapies such as Volanesorsen (Ionis Pharmaceuticals), Lipaglyn (Zydus Cadila) and some other are expected to change the treatment landscape of Lipodystrophy Syndrome (LS) in upcoming years.

Lipodystrophy Syndrome (LS) Market Outlook

The Lipodystrophy Syndrome (LS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Lipodystrophy Syndrome (LS) in 7MM is expected to change from the study period 2016-2027.

Lipodystrophy Syndrome (LS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lipodystrophy Syndrome (LS) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Lipodystrophy Syndrome (LS) Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Lipodystrophy Syndrome (LS) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving Lipodystrophy Syndrome (LS) market
Organize sales and marketing efforts by identifying the best opportunities for Lipodystrophy Syndrome (LS) market
To understand the future market competition in the Lipodystrophy Syndrome (LS) market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Ionis Pharmaceuticals
  • Zydus Cadila
  • MORE

1. Report Introduction

2. Lipodystrophy Syndrome (LS) Market Overview at a Glance
2.1. 7 Major Market Size of Lipodystrophy Syndrome (LS) in 2017
2.2. 7 Major Market Size of Lipodystrophy Syndrome (LS) in 2027

3. Disease Background and Overview: Lipodystrophy Syndrome (LS)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. 7MM Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
4.2. 7MM Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
4.3. 7MM Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)

5. Lipodystrophy Syndrome (LS): Country- Wise Epidemiology
5.1. United States
5.2. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.3. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.4. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5. EU-5
5.5.1. Assumptions and Rationale
5.5.2. Germany
5.5.2.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.2.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.2.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.3. France
5.5.3.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.3.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.3.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.4. Italy
5.5.4.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.4.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.4.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.5. Spain
5.5.5.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.5.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.5.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.6. United Kingdom
5.5.6.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.6.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5.6.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.6. Japan
5.6.1. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.6.2. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.6.3. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)

6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Marketed drug
7.1.1. Myalept: Bristol-Myers Squibb
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages & Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile
To be continued in the report

8. Emerging Therapies
8.1. Key Cross Competition
8.1.1. Volanesorsen: Ionis Pharmaceuticals
8.1.1.1. Regulatory Milestones
8.1.1.2. Clinical Development
8.1.1.3. Product Profile
8.1.1.4. Clinical Pipeline Activity
8.1.1.4.1. Ongoing Trials Information
8.1.1.4.2. Clinical Trial by Phase
8.1.2. Lipaglyn: Zydus Cadila
8.1.2.1. Regulatory Milestones
8.1.2.2. Clinical Development
8.1.2.3. Product Profile
8.1.2.4. Clinical Pipeline Activity
8.1.2.4.1. Ongoing Trials Information
8.1.2.4.2. Clinical Trial by Phase
To be continued in report

9. Lipodystrophy Syndrome (LS) Market Size
9.1. Key Findings
9.2. Total 7MM Lipodystrophy Syndrome (LS) Market Analysis
9.2.1. Overview of Total Lipodystrophy Syndrome (LS) Market
9.2.2. Market size of Lipodystrophy Syndrome (LS) Market by 7MM (2016-2027)

10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.1.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.2.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.3.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.4.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.5.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.6.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Lipodystrophy Syndrome (LS)
10.7.2. Market Size of Lipodystrophy Syndrome (LS) by Therapies

11. Market Drivers

12. Market Barriers

13. Report Methodology
13.1. Sources Used

14. Capabilities

15. Disclaimer

16. About the Publisher

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ionis Pharmaceuticals
  • Zydus Cadila
  • Bristol-Myers Squibb
Note: Product cover images may vary from those shown
Adroll
adroll